WallStreetZenWallStreetZen

NASDAQ: INZY
Inozyme Pharma Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

INZY earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$71.2M
Current Profit Margin
0%

INZY Return on Equity

Current Company
-55.9%
Current Industry
-63.5%
Current Market
188%
INZY's Return on Equity (-55.9%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when INZY announces earnings.

INZY Return on Assets

Current Company
-40.7%
Current Industry
2.9%
INZY is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

INZY Return on Capital Employed

Current Company
-36.44%
Current Industry
19.5%
INZY's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

INZY vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
INZY$0.00-$66.51M-$71.17MN/AN/A
NBTX$38.93M-$25.02M-$42.69M+58.68%N/A
EPIX$0.00-$25.69M-$25.80MN/AN/A
AKBA$194.62M-$4.05M-$51.93M-1.30%N/A
GLUE$0.00-$128.79M-$135.35MN/AN/A
View Top Biotech Stocks

INZY earnings dates

Next earnings date
Jun 12, 2024

Inozyme Pharma Earnings & Revenue FAQ

What were INZY's earnings last quarter?

On Invalid Date, Inozyme Pharma (NASDAQ: INZY) reported Q4 2023 earnings per share (EPS) of -$0.35, up 16.67% year over year. Total Inozyme Pharma earnings for the quarter were -$21.54 million. In the same quarter last year, Inozyme Pharma's earnings per share (EPS) was -$0.42.

If you're new to stock investing, here's how to buy Inozyme Pharma stock.

What was INZY's earnings growth in the past year?

As of Q2 2024, Inozyme Pharma's earnings has grown year over year. Inozyme Pharma's earnings in the past year totalled -$71.17 million.

What is INZY's earnings date?

Inozyme Pharma's earnings date is Invalid Date. Add INZY to your watchlist to be reminded of INZY's next earnings announcement.

What was INZY's revenue last quarter?

On Invalid Date, Inozyme Pharma (NASDAQ: INZY) reported Q4 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Inozyme Pharma's revenue was $0.00.

What was INZY's revenue growth in the past year?

As of Q2 2024, Inozyme Pharma's revenue has grown null year over year. Inozyme Pharma's revenue in the past year totalled $0.00.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.